Thomas Leggett

Mr. Leggett, Sernior Vice President of Finance, Chie Financial Officer, began his career in Management Consulting at Mitchell Madison Group before transitioning to Elance, Inc., a Kleiner, Perkins, Caufield and Byers-backed internet start-up company. After earning his MBA, he started his investment banking career in the J.P. Morgan Securities Healthcare Group. His transactions included the acquisition of Guidant Corporation by Boston Scientific, the initial public offering of Coley Pharmaceuticals and an equity offering for Celgene. Following his time at J.P. Morgan, Leggett became a Vice President at Lazard Frères & Company, where he worked on the acquisitions of PolyMedica by Medco Health Solutions and Viasys Healthcare by Cardinal Health, among other transactions.

Mr. Leggett then spent five years at UBS Securities as an Executive Director in the Healthcare Group with a primary focus in the biopharmaceutical sector. His transactions during this time included advising Akebia Therapeutics, Amgen, Baxter International, Bristol-Myers Squibb and Momenta Pharmaceuticals.

In 2015, Leggett joined Purdue Pharma L.P. as Treasurer and Head of Business Development Finance. During his time at Purdue, the company announced five strategic transactions, including the worldwide collaboration to develop and commercialize lemborexant with Eisai Co., Ltd. and the alliance for the joint U.S. commercialization of Symproic® (naldemedine) with Shionogi & Co., Ltd.

Mr. Leggett received his Bachelor of Arts in Economics from Columbia University and earned his Master’s in Business Administration in Finance from The Wharton School at the University of Pennsylvania.